Followers | 1085 |
Posts | 26830 |
Boards Moderated | 11 |
Alias Born | 01/11/2016 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, April 18, 2020 11:47:56 AM
https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
Recent RCUS News
- Arcus Biosciences Announces New Employment Inducement Grants • Business Wire • 06/25/2024 08:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:53:54 PM
- Arcus Biosciences Announces New Employment Inducement Grants • Business Wire • 06/11/2024 08:35:00 PM
- Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers • Business Wire • 06/10/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 10:20:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 10:20:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 10:19:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:28:54 PM
- Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/06/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:18:10 PM
- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer • Business Wire • 06/02/2024 12:00:00 PM
- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer • Business Wire • 06/02/2024 12:00:00 PM
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers • Business Wire • 06/01/2024 12:00:00 PM
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers • Business Wire • 06/01/2024 12:00:00 PM
- Arcus Biosciences Announces New Employment Inducement Grants • Business Wire • 05/24/2024 08:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:59:24 PM
- Arcus Biosciences Announces New Employment Inducement Grants • Business Wire • 05/09/2024 08:35:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:08:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:12 PM
- Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update • Business Wire • 05/08/2024 08:02:00 PM
- Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024 • Business Wire • 05/02/2024 08:05:00 PM
- Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting • Business Wire • 04/24/2024 08:00:00 PM
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update • Business Wire • 04/23/2024 08:05:00 PM
- Arcus Biosciences Announces New Employment Inducement Grants • Business Wire • 04/09/2024 08:35:00 PM
- Arcus Biosciences Announces New Employment Inducement Grants • Business Wire • 03/26/2024 08:35:00 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM